OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Structure of SARS-CoV-2 spike protein	150
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19	128
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection	106
Current challenges to virus discovery by meta-transcriptomics	68
Future considerations for the mRNA-lipid nanoparticle vaccine platform	66
Zoonotic disease and virome diversity in bats	63
Global overview and major challenges of host prediction methods for uncultivated phages	62
Coronavirus entry: how we arrived at SARS-CoV-2	57
Structure and function of SARS-CoV-2 polymerase	57
The virome of vector mosquitoes	57
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing	55
A structural view of the SARS-CoV-2 virus and its assembly	55
Animal models for SARS-CoV-2	54
The healthy human virome: from virus–host symbiosis to disease	51
Engineering therapeutic phages for enhanced antibacterial efficacy	50
Recent advances in understanding plant antiviral RNAi and viral suppressors of RNAi	46
Structure, function and assembly of the long, flexible tail of siphophages	46
Viral Z-RNA triggers ZBP1-dependent cell death	44
Cell-to-cell movement of plant viruses via plasmodesmata: a current perspective on potyviruses	44
Anti-viral protective capacity of tissue resident memory T cells	40
European regulatory aspects of phage therapy: magistral phage preparations	40
COVID-19, the first pandemic in the post-genomic era	40
Perspective on taxonomic classification of uncultivated viruses	38
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	37
Host cell-intrinsic innate immune recognition of SARS-CoV-2	37

Entry of influenza A virus into host cells — recent progress and remaining challenges	36
Tombusviruses orchestrate the host endomembrane system to create elaborate membranous replication organelles	35
Mitigation of evolved bacterial resistance to phage therapy	34
Viral structural proteins as targets for antivirals	32
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world	32
Detection of viruses by inflammasomes	31
Current view and perspectives in viroid replication	30
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	30
Rotavirus cell entry: not so simple after all	30
Adenovirus – a blueprint for gene delivery	29
Hepatitis B virus–host interactions and novel targets for viral cure	29
Drug resistance mutations in HIV: new bioinformatics approaches and challenges	29
Animal models of SARS-CoV-2 transmission	28
Epigenetic control of the Epstein-Barr lifecycle	28
Digital phagograms: predicting phage infectivity through a multilayer machine learning approach	28
Measles immunity and immunosuppression	28
Immune system control of hepatitis C virus infection	27
An overview of the current state of phage therapy for the treatment of biofilm-related infections	26
Natural killer cells and unconventional T cells in COVID-19	26
Molecular dynamics of the viral life cycle: progress and prospects	25
Progress and pitfalls of a year of drug repurposing screens against COVID-19	25
The gut virome in inflammatory bowel diseases	24
Development of plant-made monoclonal antibodies against viral infections	23
Proteases and variants: context matters for SARS-CoV-2 entry assays	23
R gene mediated defense against viruses	23
Targeting of viral RNAs by Upf1-mediated RNA decay pathways	23
The long and winding road: human papillomavirus entry and subcellular trafficking	23
Mapping the diverse structural landscape of the flavivirus antibody repertoire	22
UPR signaling at the nexus of plant viral, bacterial, and fungal defenses	22
Remdesivir for the treatment of Covid-19: the value of biochemical studies	22
Revisiting an old friend: new findings in alphavirus structure and assembly	22
Tissues: the unexplored frontier of antibody mediated immunity	21
Antiviral immunity triggered by infection-induced host transposable elements	21
Broadly neutralizing antibodies against HIV-1 and concepts for application	21
Evolution of the interferon response: lessons from ISGs of diverse mammals	21
Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone	21
Phage therapy for secondary bacterial infections with COVID-19	20
Unresolved questions in the zoonotic transmission of MERS	20
Assembly of the virome in newborn human infants	20
Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis	20
The enigmatic roles of Anelloviridae and Redondoviridae in humans	20
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	19
Virus genomics: what is being overlooked?	19
The surface glycoproteins of hantaviruses	18
Advances in human monoclonal antibody therapy for HBV infection	18
The origin of Human Papillomavirus (HPV) — induced cervical squamous cancer	18
The influence of microbiota-derived metabolites on viral infections	18
Endocytosis of Bacteriophages	18
Cryo-electron microscopy of nodavirus RNA replication organelles illuminates positive-strand RNA virus genome replication	18